S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

ALRN Aileron Therapeutics Inc

2.11

0.00 (0.00%)

Pre Market

Last Updated: 11:00:00

Delayed by 15 minutes

Form ARS - Annual Report to Security Holders

Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Aileron Therapeutics Charts.

Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Aileron Therapeutics Charts.

Aileron Therapeutics Inc News

Form 8-K - Current report
Saturday 11 January 2025 (1 month ago) • Edgar (US Regulatory)

Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Saturday 11 January 2025 (1 month ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 10 December 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 7 December 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 7 December 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 7 December 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 5 December 2024 (3 months ago) • Edgar (US Regulatory)

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Friday 15 November 2024 (3 months ago) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 15 November 2024 (3 months ago) • Edgar (US Regulatory)

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Wednesday 13 November 2024 (3 months ago) • PR Newswire (US)

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Thursday 31 October 2024 (4 months ago) • PR Newswire (US)

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Sunday 13 October 2024 (4 months ago) • PR Newswire (US)

More Aileron Therapeutics Inc News Articles

Australian SE All Ordina...

S&P ASX 300 Metals and M...

Sterling vs AUD

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions